EUROPEAN RESPIRATORY *journal*

FLAGSHIP SCIENTIFIC JOURNAL OF ERS

Early View

Original research article

Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study

Ismail M Osmanov, Ekaterina Spiridonova, Polina Bobkova, Aysylu Gamirova, Anastasia Shikhaleva, Margarita Andreeva, Oleg Blyuss, Yasmin El-Taravi, Audrey DunnGalvin, Pasquale Comberiati, Diego G Peroni, Christian Apfelbacher, Jon Genuneit, Lyudmila Mazankova, Alexandra Miroshina, Evgeniya Chistyakova, Elmira Samitova, Svetlana Borzakova, Elena Bondarenko, Anatoliy A Korsunskiy, Irina Konova, Sarah Wulf Hanson, Gail Carson, Louise Sigfrid, Janet T Scott, Matthew Greenhawt, Elizabeth A Whittaker, Elena Garralda, Olivia Swann, Danilo Buonsenso, Dasha E Nicholls, Frances Simpson, Christina Jones, Malcolm G Semple, John O Warner, Theo Vos, Piero Olliaro, Daniel Munblit, Sechenov StopCOVID Research Team

Please cite this article as: Osmanov IM, Spiridonova E, Bobkova P, *et al*. Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. *Eur Respir J* 2021; in press (https://doi.org/10.1183/13993003.01341-2021).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study

Ismail M Osmanov MD PhD[1,2*], Ekaterina Spiridonova BSc[3*], Polina Bobkova BSc[3*], Aysylu Gamirova BSc[3*], Anastasia Shikhaleva BSc[3*], Margarita Andreeva BSc[3*], Oleg Blyuss PhD[3,4,*], Yasmin El-Taravi BSc[3], Audrey DunnGalvin PhD[3,5], Pasquale Comberiati MD[6], Diego G Peroni MD PhD[6], Christian Apfelbacher PhD[7], Jon Genuneit MD PhD[8], Lyudmila Mazankova MD PhD[9], Alexandra Miroshina MD PhD[1], Evgeniya Chistyakova MD PhD[10], Elmira Samitova MD PhD[1,9], Svetlana Borzakova MD PhD[2,11], Elena Bondarenko[3], Anatoliy A Korsunskiy MD PhD[3], Irina Konova MD[1], Sarah Wulf Hanson PhD[12], Gail Carson MD PhD[13], Louise Sigfrid MD PhD[13], Janet T Scott MD PhD[14], Matthew Greenhawt MD MBA[15], Elizabeth A Whittaker MD PhD[16], Elena Garralda MD PhD[17], Olivia Swann MD PhD[18,19], Danilo Buonsenso MD[20,21,22], Dasha E Nicholls MD PhD[17], Frances Simpson MSc[23], Christina Jones MD PhD[24], Malcolm G Semple MD PhD[25,26], John O Warner MD FMedSci [27], Theo Vos PhD[12], Piero Olliaro MD PhD[13], Daniel Munblit MD PhD[3,27,28*] and Sechenov StopCOVID Research Team

1. ZA Bashlyaeva Children's Municipal Clinical Hospital, Moscow, Russia
2. Pirogov Russian National Research Medical University, Moscow, Russia
3. Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
4. School of Physics, Astronomy and Mathematics, University of Hertfordshire, College Lane, Hatfield, United Kingdom
5. School of Applied Psychology, University College Cork, Cork City, Ireland
6. Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy
7. Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto von Guericke University Magdeburg, Magdeburg, Germany
8. Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany
9. Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
10. Department of Paediatrics and Paediatric Rheumatology, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
11. Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department, Moscow, Russia
12. Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA
13. ISARIC Global Support Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK
14. MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
15. Department of Pediatrics, Section of Allergy/Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, United States
16. Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, UK
17. Division of Psychiatry, Imperial College London, London, UK
18. Department of Child Life and Health, University of Edinburgh, Edinburgh, UK
19. Royal Hospital for Children, Paediatric Infectious Diseases, Glasgow, UK

20. Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
21. Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy
22. Center for Global Health Research and Studies, Università Cattolica del Sacro Cuore, Roma, Italia
23. Coventry University, Coventry, UK
24. School of Psychology, Faculty of Health & Medical Sciences, University of Surrey, Guildford, UK
25. Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
26. Department of Respiratory Medicine, Alder Hey Children's Hospital, Liverpool, UK
27. Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom
28. Research and Clinical Center for Neuropsychiatry, Moscow, Russia

*Authors contributed equally to the paper.

Corresponding author:
Daniel Munblit, MD, PhD. Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia and Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom
Email: daniel.munblit08@imperial.ac.uk

Sechenov StopCOVID Research Team (Group authors)

Elina Abdeeva[1], Nikol Alekseeva[1], Anastasiia Bairashevskaia[1], Dina Baimukhambetova[1], Lusine Baziyants[1], Anna Berbenyuk[1], Tatiana Bezbabicheva[1], Julia Chayka[1], Salima Deunezhewa[1], Yulia Filippova[1], Svetlana Gadetskaya[2], Anastasia Gorina[1], Cyrill Gorlenko[1], Yulia V Ivanova[2], Margarita Kalinina[1], Bogdan Kirillov[1], Herman Kiseljow[1], Natalya Kogut[1], Mariia Korgunova[1], Anastasia Kotelnikova[1], Alexandra Krupina[1], Anna Kuznetsova[1], Anastasia Kuznetsova[1], Veronika Laukhina[1], Baina Lavginova[1], Elza Lidjieva[1], Nadezhda Markina[1], Daria Nikolaeva[1], Georgiy Novoselov[1], Polina Petrova[1], Erika Porubayeva[1], Kristina Presnyakova[1], Anna Pushkareva[1], Mikhail Rumyantsev[1], Ilona Sarukhanyan[1], Jamilya Shatrova[1], Nataliya Shishkina[1], Anastasia Shvedova[1], Valeria Ustyan[1], Maria Varaksina[1], Ekaterina Varlamova[1], Margarita Yegiyan[1], Elena Zuykova[1]

1. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
2. Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

The names of the authors are in alphabetic order

Conflict of interest: J. Genuneit reports working as a project manager of unrestricted research grants on the composition of breast milk to the Ulm University and Leipzig University with funding from Danone Nutricia Research. M.G. Semple reports grants from DHSC National Institute of Health Research UK, grants from Medical Research Council UK, grants from Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool outside the submitted work; he also reports a minority ownership at Integrum

Scientific LLC, Greensboro, NC, USA outside the submitted work. T. Vos reports personal fees for work on Global Burden of Disease Study from Bill and Melinda Gates Foundation, outside the submitted work. C. Apfelbacher has received lecture fees from Astrazeneca, and is a member of a group developing a core outcome set for long COVID, outside the submitted work. All other authors report no relevant conflict of interests.

ABSTRACT

Background The long-term sequelae of coronavirus disease 2019 (Covid-19) in children remain poorly characterised. This study aimed to assess long-term outcomes in children previously hospitalised with Covid-19 and associated risk factors.

Methods This is a prospective cohort study of children (≤18 years old) admitted with confirmed Covid-19. Children admitted to the hospital between April 2, 2020 and August 26, 2020, were included. Telephone interview using the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Covid-19 Health and Wellbeing paediatric follow-up survey. Persistent symptoms (>5 months) were further categorised by system(s) involved.

Findings 518 of 853 (61%) of eligible children were available for the follow-up assessment and included in the study. Median age was 10.4 years (IQR, 3–15.2) and 270 (52.1%) were girls; median follow-up since hospital discharge was 256 (223-271) days. At the time of the follow-up interview 126 (24.3%) participants reported persistent symptoms among which fatigue (53, 10.7%), sleep disturbance (36, 6.9%,) and sensory problems (29, 5.6%) were the most common. Multiple symptoms were experienced by 44 (8.4%) participants. Risk factors for persistent symptoms were: older age “6-11 years” (odds ratio 2.74 (95% confidence interval 1.37 to 5.75) and “12-18 years” (2.68, 1.41 to 5.4); and a history of allergic diseases (1.67, 1.04 to 2.67).

Interpretation A quarter of children experienced persistent symptoms months after hospitalization with acute covid-19 infection, with almost one in ten experiencing multi-system involvement. Older age and allergic diseases were associated with higher risk of persistent symptoms at follow-up.

INTRODUCTION

Emerging data suggest that a substantial proportion of people experience ongoing symptoms including fatigue and muscle weakness, breathlessness, and neurological problems more than 6 months after the acute phase of Covid-19 [1, 2]. This phenomenon is commonly referred to as 'long Covid', a term defined by patient groups, and also known as post-Covid syndrome, the post-Covid-19 condition [3] or 'Covid long-haulers [4, 5]. Recent population data from the UK reported that the highest prevalence of long Covid after 12 weeks was among those aged 25 to 34 years (18.2%) and lowest in the 2 to 11 years age bracket (7.4%) [6].

Evidence on post-acute covid condition and long term outcomes in children is still limited to small studies with more than half having at least one persisting symptom 4 months after covid-19 infection [7]. However, a recent publication from Australia suggested that only 8% of children aged 0-19 years (median 3 years) had ongoing symptoms 3-6 months after predominantly mild covid-19 infection. The limitation of the study as acknowledged by the authors was the low age range. This mandates the larger numbers inclusion particularly of older children in future studies [8].

There is a need to assess the long-term consequences of Covid-19 in paediatric populations [9], to inform clinicians, researchers and public health experts and address the impacts of this condition on those affected and their families and to inform discussions on vaccination of children. This cohort study aimed to investigate the incidence of and risk factors for long-term Covid-19 outcomes in children post-hospital discharge. We used the standardised follow-up data collection protocol developed by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Global Paediatric Covid-19 follow-up working group [10].

METHODS

Study design, setting and participants

This is a prospective cohort study of children (≤18 years old) admitted with suspected or confirmed Covid-19 to Z.A. Bashlyaeva Children's Municipal Clinical Hospital in Moscow, Russia. This large tertiary university hospital can accommodate up to 980 children at a time and served as the primary Covid-19 hospital for children residing in Moscow city. Children admitted to the hospital during the first wave of the pandemic, between April 2, 2020 and August 26, 2020, with reverse transcriptase polymerase chain reaction (RT-PCR) confirmed

SARS-CoV-2 infection were included. The parents of these children were contacted between January 31, 2021 and February 27, 2021 to complete a follow-up survey for this study.

The acute-phase dataset included demographics, symptoms, co-morbidities, chest computer tomography (CT), supportive care, and clinical outcomes at discharge. This study was approved by the Moscow City Independent Ethics Committee (abbreviate 1, protocol number 74). Parental consent was sought during hospital admission and consent for the follow-up interview was sought via verbal confirmation during telephone interview.

Interviews were undertaken by a team of medical students with experience gained in previous Covid-19 research [2, 11] who underwent standardised training in telephone assessment, REDCap data entry and data security. Assessments were conducted via interviews with the parents/carers. Non-responders were contacted by telephone three times before considering them lost to follow-up. Information about the current condition and persisting symptoms was collected using the version 1.0 of the ISARIC COVID-19 Health and Wellbeing Follow-Up Survey for Children, to assess patients' physical and psychosocial wellbeing and behaviour, with local adaptations (addition of questions related to signs/symptoms presence which symptom duration), translated into Russian. The protocol was registered at The Open Science Framework [12]. The follow-up survey documented data on demographics, parental perception of changes in their child's emotional and behavioural status (including reasons for a change covid-19, pandemic or both), previous vaccination history, hospital stay and readmissions, mortality (after the initial index event), history of newly developed symptoms between discharge and the follow-up assessment, including symptom onset and duration, and overall health condition compared to prior to the child's Covid-19 onset (**Supplementary file**). To assess the prevalence of symptoms over time parents were asked the following: (a) *Within the last seven days, has your child had any of these symptoms, which were NOT present prior to their Covid-19 illness? (If yes, please indicate below and the duration of the symptom/s)* and (b) *Please report any symptoms that have been bothering your child since discharge that are not present today. Please specify the time of onset and duration of these symptoms.*

Data management

REDCap electronic data capture tools (Vanderbilt University, Nashville, TN, USA) hosted at Sechenov University and Microsoft Excel (Microsoft Corp, Redmond, WA, USA) were used for data collection, storage and management [13, 14]. The baseline characteristics, including demographics, symptoms on admission and comorbidities were extracted from EMRs and entered into REDCap.

Exposure and outcome variables

For the purposes of this study, we defined "persistent symptoms" as symptoms present at the time of the follow-up interview and lasting for over 5 months. These were subcategorised into respiratory, neurological, sensory, sleep, gastrointestinal, dermatological, cardiovascular, fatigue and musculoskeletal (**Table S1**) informed by previously published literature [15, 16] and ISARIC Global Paediatric Covid-19 follow-up working group discussions.

Allergic diseases were defined as a presence of any of the following: asthma, allergic rhinitis, eczema or food allergy. Participants age categories were based on Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Terminology [17]. Severe disease was defined as having received non-invasive ventilation, invasive ventilation or admission to the paediatric intensive care unit (PICU) during the hospital admission.

Health status before Covid-19 and at the time of the interview was assessed using a 0 to 100 wellness scale [18], where 0 was the worst possible health and 100 the best possible health.

Statistical analysis

Descriptive statistics were calculated for baseline characteristics. Continuous variables were summarised as median (with interquartile range) and categorical variables as frequency (percentage). The chi-squared test or Fisher's exact test was used for testing hypotheses on differences in proportions between groups. The Wilcoxon rank-sum test was used for testing the hypotheses on differences between groups.

We performed multivariable logistic regression to investigate associations of demographic characteristics, co-morbidities (limited to those reported in ≥5% of participants), presence of pneumonia during acute infection and severity of Covid-19 with persistent symptom categories presence at the time of the follow-up interview. We included all participants for whom the variables of interest were available in the final analysis, without imputing missing data. The differing denominators used indicate missing data. Odds ratios were calculated together with 95% confidence intervals (CIs).

Upset plots were used to present the coexistence of persistent symptom categories. Two-sided p-values were reported for all statistical tests, a p-value below 0.05 was considered to be statistically significant. Statistical analysis was performed using R version 3.5.1. Packages used included dplyr, lubridate, ggplots2, plotrix and UpSetR.

Patient and public involvement

The survey was developed by the ISARIC Global Paediatric Covid-19 follow-up working group and informed by a wide range of global stakeholders with expertise in infectious diseases, critical care, paediatrics, epidemiology, allergy-immunology, respiratory medicine, psychiatry, psychology and methodology and patient representatives. The survey was distributed to the members of the patient group and suggestions from parents/carers were implemented.

RESULTS

Study population

All 853 children hospitalised with suspected Covid-19 to the hospital between April 2, 2020 and August 26, 2020 were discharged alive (**Figure 1**). Of 836 patients with accurate contact information, parents of 518 RT-PCR positive children agreed to be interviewed (response rate 62%) and were included in the analysis.

The median age was 10.4 years (IQR, 3-15.2; range, 2 days–18 years), 272 (52.2%) were girls. Median follow-up time since hospital admission was 268 days (IQR 233-284). Children had a median of 8 (IQR, 4-9) years of formal school education and a median of 4 (IQR, 3-5) family members were residing in the household (**Table 1**).

The most common pre-existing comorbidity in this cohort was food allergy (13%, 67/514), followed by allergic rhinitis and asthma (9.7%, 50/514), gastrointestinal problems (9.3%, 48/514), eczema (8.8%, 45/514) and neurological problems (8.4%, 43/514). Parents of 55.3% (284/514) children did not report any comorbidities. Fever (83.6%, 427/511), cough (55.7%, 284/510), rhinorrhea (54.3%, 278/512) and fatigue (38.9%, 197/506) were the most common presenting symptoms at the time of the hospital admission (**Table S2**). 37.3%, 192/515 of patients had pneumonia during hospital stay, 2.7%, 14/515 had severe disease, which required non-invasive ventilation/invasive ventilation or admission to PICU. Treatments received during the hospital admission are presented in **Table S3**.

At the time of the follow-up interview, parents of 24.7% (128) children reported at least one persistent symptom, with fatigue 10.6% (53/496), insomnia 5.19% (26/501), disturbed smell 4.7% (22/467) and headache 3.5% (17/486) being the most common. Detailed information on symptoms and duration is presented in **Table S4**.

The prevalence of the symptoms present at the time of discharge declined over time (**Figure 2**). Number of children with fatigue fell from 15.8% (82/518) at the time of discharge to 8.8% (45/513) 6-7 months later, altered sense of smell from 8.7% (45/518) to 4.7% (24/514), sleep disturbance 7.5% (39/518) to 5.8% (30/515), altered sense of taste from 5.6% (29/518) to 3.1% (16/515), headache from 4.6% (24/518) to 3.5% (18/517), and breathing difficulties from 3.9% (20/518) to 1% (5/517), respectively. The prevalence of the most common symptoms including symptoms that developed some time after discharge are shown in **Figure S1**.

With regard to persistent symptom categories (**Table S1**), fatigue was the most commonly reported in 10.6% (53/498) of patients at the time of assessment, followed by sleep disturbance 7.2% (36/501), sensory problems 6.2% (29/467), gastrointestinal 4.4% (22/499) and dermatological 3.6% (18/496) problems. A smaller number of patients experienced neurological 3% (14/465), respiratory 2.5% (12/489), cardiovascular 1.9% (9/470) and musculoskeletal 1.8% (9/489) problems long-term.

A total of 8.5% (44) participants reported persistent symptoms from more than one category at the time of the follow-up assessment. Most commonly co-occurring categories were fatigue and sleep problems in 1.9% (10) of children, and fatigue and sensory problems were present in 1.5% (8) of participants. 2.7% (14) of children had persistent symptoms from three or more different categories. Co-existence of persistent symptom categories at the time of the follow-up is presented in the upset plot (**Figure 3**).

The scores on the wellness scale for children with one or two or more persistent symptoms significantly declined when compared to before Covid-19 onset from 90 (80-100) to 82.5 (70-93.8) and from 90 (80-95) to 70 (60-80) ($p<0.001$ for all comparisons), respectively. Children who did not experience any persistent symptoms did not report any significant changes in wellness when asked to compare to how they felt before their acute Covid-19 illness. We also assessed emotional difficulties, social relationships, and activity levels in children (**Tables S4 - S5**). Parents related the following changes to Covid-19 illness, and not to the pandemic in general: less eating in 4.5% (23/512) of children, less sleeping in 3.5% (18/511) and more sleeping in 2% (10/511), reduced physical activity in 4.7% (24/512) and child becoming less emotional in 4.3% (22/511). In contrast, parents attributed changes to social activities to the pandemic in general rather than to the Covid-19 illness: 12% (58/485) of children were spending less time with their friends in person, while 13% (61/470) were spending more time with friends remotely, with less than one percent of parents attributing these changes to Covid-19 illness. 23% (110/478) of children were spending more time

watching television, playing video/computer games or using social media for educational purposes, with 92.9% of parents associating these changes with the pandemic in general rather than the Covid-19 illness.

In multivariable regression analysis, older age group was associated with persistent symptoms (**Figure 4**). When compared with children under two years of ages, those ages 6-11 years had an odds ratio of 2.74 (95% confidence interval 1.37 to 5.75) of persistent symptoms and those 12-18 years of age (OR 2.68, 95% CI 1.41 to 5.4) both vs. <2 years. Another predictor associated with persistent symptoms was allergic diseases (OR 1.67, 95% CI 1.04 to 2.67). Similar patterns were seen for children with co-existence of persistent symptoms from 2 or more categories: 6-11 years of age (OR 2.49, 95% CI 1.02 to 6.72), 12-18 years of age (OR 3.18, 95% CI 1.43 to 8.11) both vs. <2 years.

We ran an additional regression analyses, using "age" as a continuous variable (**Figure S2**) which brought similar result. When subgroup analyses were performed in the age group of six years and above, severe acute Covid-19 was associated with persistent symptoms (OR 6.14, 95% CI 1.27 to 43.94) and excessive weight and obesity with co-existence of persistent symptoms from 2 or more categories (OR 2.89, 95% CI 1.12 to 7.15) (**Figure S3**).

DISCUSSION

To our knowledge, this is the largest prospective paediatric cohort study with the longest follow-up, assessing symptom prevalence and duration of long COVID in children and adolescents with laboratory confirmed SARS-CoV-2 infection post hospital discharge. We found that a quarter of children and adolescents had persistent symptoms at the time of the follow-up with fatigue, sleep disturbance and sensory problems being the most common. Almost one in ten reported multi-system impacts with two or more categories of persistent symptoms at the time of the follow-up. Children in mid-childhood and adolescence (age 6-18) were at higher risk of persistent symptoms at the time of the follow-up. Although prevalence of symptoms declined over time, a substantial proportion experienced problems many months after discharge.

Although many children experienced symptoms, such as fatigue, disturbed smell and taste, sleep and respiratory problems, hair loss and headaches at the time of the hospital discharge, we witnessed a steady decline in the symptom prevalence over time. This was particularly evident for fatigue and smell disturbance. Prevalence of some symptoms such as headache, and sleep problems declined slower, which may be driven by psychological mechanisms rather than pathophysiologic virus infection effects [19]. A limitation of these findings is that

symptom onset and duration was recalled at the single follow-up interview in our study; this may be overcome with repeated follow-ups at appropriate intervals to limit potential recall imprecision. There are very few studies assessing long COVID in children and adolescents; a previous smaller study from Italy found similar persisting symptoms during a shorter follow-up [20]. In line with our results, previous research demonstrated symptoms fading over time in adults [15] but data are still limited as most of the published cohort studies do not measure symptom duration, but rather assess their presence at a single follow-up.

We found that almost one in ten children had multisystem impacts with two or more categories of persistent symptoms present at the time of the follow-up. Similar numbers were previously reported in the Russian adult population [2] and patients with clusters of different symptoms were described in the UK [21]. Patients with multisystem involvement will represent the primary target for the future research and intervention strategies development.

Age was significantly associated with persistent symptom presence at the time of the follow-up, with children above 6 years of age being at higher risk. To our knowledge, risk factors for long Covid in children have not been investigated in previous studies, so we may draw comparisons with the data from adult cohorts only. Previous data suggest that long Covid is prevalent in adults [1, 2, 21-24] and that age is associated with a higher risk of long Covid [21, 23]. An Australian follow-up study of 151 children (median 3 years) who had predominantly mild acute covid-19 infection [8] found only 8% with on-going long-covid symptoms. As acknowledged by the authors the low median age may be the main reason for the low long-covid prevalence and our study substantiates this. We also found that in children of six years of age and above, severe acute Covid-19 was associated with persistent symptoms and excessive weight and obesity with multisystem involvement, but confidence intervals were wide and these findings require confirmation on a larger sample size to make any firm conclusions.

We found that allergic diseases in children were also associated with a higher risk of long Covid. This is in agreement with adult studies from Russia [2] and the UK [21] reporting asthma to be associated with development of long Covid. Recent data suggested that COVID-19 consequences may be linked with the mast cell activation syndrome [25] and the Th-2 biased immunological response in children with allergic diseases may be responsible for an increased risk of long-term consequences from the infection. This highlights importance of further research of potential underlying immunological and autoimmune mechanisms of long Covid [26].

Apart from physical symptoms we assessed emotional and behavioural changes. Although most parents reported no changes, one in twenty parents noticed changes in their children, which they attributed to Covid-19 illness rather than the general situation during the pandemic. These included changes in eating, sleeping, emotional wellbeing and physical activities. Over one in ten parents noted that their children were spending less time in face-to-face communication and more time interacting with their friends remotely and spending time online for both educational and non-educational purposes. These changes were largely attributed to the general situation during the pandemic rather than to the Covid-19 illness. The "lockdown" measures were implemented in Moscow in the middle of March and lasted until June 2020. Restrictions included self-isolation, public places closures, including schools/universities social distancing, etc. Pandemic resulted in increased anxiety levels among population, which was associated with increased media consumption [27]. The effect of pandemic, illness or both should be further studied in the future research.

A major strength of this study is that it was based on the ISARIC COVID-19 Health and Wellbeing Follow-Up Survey for Children which will assist with data harmonisation and comparison with other international studies in the future. Another strength is the large sample size of confirmed Covid-19 infected children, and this cohort has the longest follow-up assessment of hospitalised children to date. Stratification to determine if the symptoms were persistent following Covid-19 and assessment of trends over time were other novel aspects of the study. At the same time, this cohort study has several limitations. First, the study population only included patients within Moscow, although regional clustering is common to many cohort studies published during the Covid-19 pandemic. Second, it included only hospitalised children, not representative of paediatric population. Third, we did not have a control group of previously hospitalised children not experiencing Covid-19 infection. Fourth, some patients may have developed additional comorbidities or complications since the hospital discharge, which were not appropriately captured and could potentially affect the wellbeing and symptom prevalence and persistence. Fifth, the parents/caregivers were interviewed in this study and not children themselves. There is also a risk of selection bias due to recruitment of the hospitalised population and recall bias in reporting symptoms which were non-existent at the time of the follow-up and potential selection bias with those with symptoms more likely to agree to survey.

The study used to generate this data within the ISARIC WHO Clinical Characterisation Protocol initiative is a prospective pandemic preparedness protocol which is agnostic to disease and has a pragmatic design to allow recruitment during pandemic conditions. The

reality of conducting research in outbreak conditions do not allow for appropriate co-enrolment of a control group, which is not practical. One of the issues which has not been addressed so far in clinical research is what control group of individuals admitted to hospital during this period when hospitals were overwhelmed with Covid-19 cases could provide a valid control group. The design of this study allows only to describe the feature of Covid-19 survivors and cannot involve a control group. Covid-19 is not just a respiratory tract infection so there is no one-fit-all control group. At present, to our knowledge, all major publications on long Covid are uncontrolled cohorts due to the difficulties of ascertaining data among controls matched for age and sex but most importantly matched for the same experiences during the pandemic aside from confirmed Covid-19 illness.

Our findings have implications for further research. Longer follow-up duration and repeated assessments combined with controls and sampling for further studies into the pathophysiology and immunology of post-Covid-19 illness sequelae are needed to inform case definitions, and intervention trials aimed to improve long term outcomes.

Conclusion

Although symptoms which were present at discharge diminished over time, even eight months after hospital discharge many children experienced persistent symptoms, with fatigue, sensory changes and sleep problems being the most common sequelae. One in ten children experienced multi-system involvement at the time of the follow-up. Age and allergic disease were the main risk factors for persistent symptoms. Future work should be multidisciplinary, prospective, preferably with a control cohort, repeated sampling and with an ability for children to report their health and wellbeing themselves, accompanied by biological sample collection to establish causative mechanisms for a better understanding of Covid-19 sequelae and help with the phenotype/endotype categorisation.

Acknowledgments

We are very grateful to the Z.A. Bashlyaeva Children's Municipal Clinical Hospital clinical staff and to the patients, parents, carers and families for their kindness and understanding during these difficult times of COVID-19 pandemic. We would like to express our very great appreciation to ISARIC Global COVID-19 follow-up working group for the survey development. We would like to thank Mr Maksim Kholopov for providing technical support in data collection and database administration. We are very thankful to Eat & Talk, Luch, Black Market, FLIP and Academia for providing us the workspace in time of need and their support of Covid-19 research. Finally, we would like to extend our gratitude to the Global ISARIC team, the ISARIC global adult and paediatric Covid-19 follow-up working group, and

ISARIC Global support centre for their continuous support, expertise and for the development of the outbreak ready standardised protocols for the data collection.

Funding statement

This study did not have external funding.

REFERENCES

1. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* 2021: 397(10270): 220-232.
2. Munblit D, Bobkova P, Spiridonova E, Shikhaleva A, Gamirova A, Blyuss O, Nekliudov N, Bugaeva P, Andreeva M, DunnGalvin A, Comberiati P, Apfelbacher C, Genuneit J, Avdeev S, Kapustina V, Guekht A, Fomin V, Svistunov AA, Timashev P, Drake TM, Hanson SW, Merson L, Horby P, Sigfrid L, Scott JT, Semple MG, Warner JO, Vos T, Olliaro P, Glybochko P, Butnaru D. Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study. *medRxiv* 2021: 2021.2002.2017.21251895.
3. Wise J. Long covid: WHO calls on countries to offer patients more rehabilitation. *BMJ* 2021: 372: n405.
4. Meeting the challenge of long COVID. *Nat Med* 2020: 26(12): 1803.
5. The L. Facing up to long COVID. *The Lancet* 2020: 396(10266): 1861.
6. Ayoubkhani D. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021. 2021 [cited 2021 6-th of April]; Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021
7. Buonsenso D, Munblit D, De Rose C, Sinatti D, Ricchiuto A, Carfi A, Valentini P. Preliminary Evidence on Long COVID in children. *medRxiv* 2021: 2021.2001.2023.21250375.
8. Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. *Lancet Child Adolesc Health* 2021.
9. Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens D, Hastie C, O'Hara M, Suett JC, Burls A, Foote C, Carson G, Olliaro P, Sigfrid L, Stavropoulou C. Characterising long-term covid-19: a rapid living systematic review. *medRxiv* 2020: 2020.2012.2008.20246025.
10. group IGPC-fuw. ISARIC Global COVID-19 paediatric follow-up. 2021 [cited 2021 24-th of April]; Available from: https://isaric.org/research/covid-19-clinical-research-resources/paediatric-follow-up/
11. Munblit D, Nekliudov NA, Bugaeva P, Blyuss O, Kislova M, Listovskaya E, Gamirova A, Shikhaleva A, Belyaev V, Timashev P, Warner JO, Comberiati P, Apfelbacher C, Bezrukov E, Politov ME, Yavorovskiy A, Bulanova E, Tsareva N, Avdeev S, Kapustina VA, Pigolkin YI, Dankwa EA, Kartsonaki C, Pritchard MG, Victor F, Svistunov AA, Butnaru D, Glybochko P. StopCOVID cohort: An observational study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city for suspected COVID-19 infection. *Clin Infect Dis* 2020.
12. Sigfrid L, Buonsenso D, DunnGalvin A, Garralda E, Jones C, Nicholls D, Swann O, Whittaker E, Warner J, Cheung K, Apfelbacher C, Simpson F, Genuneit J, Dalton H, Holden K, Bobkova P, Spiridonova E, Durashov M, Brough H, Beeretz I, Bielicki J, Robertson P, Pollock L, Greenhawt M, Murthy S, Comberiati P, Peroni D, Scott J, Hamers R, Semple M, Kim Y-J, Munblit D. Consequences of COVID-19 infection for child health and wellbeing: protocol for a prospective, observational, longitudinal study in children. 2021 [cited 2021 21-st of April]; Available from: https://osf.io/d2wjn/
13. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN, Consortium RE. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform* 2019: 95: 103208.

14. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009: 42(2): 377-381.
15. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, Redfield S, Austin JP, Akrami A. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. *medRxiv* 2020: 2020.2012.2024.20248802.
16. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. *BMJ* 2020: 370: m3026.
17. Williams K, Thomson D, Seto I, Contopoulos-Ioannidis DG, Ioannidis JPA, Curtis S, Constantin E, Batmanabane G, Hartling L, Klassen T. Standard 6: Age Groups for Pediatric Trials. *Pediatrics* 2012: 129(Supplement 3): S153-S160.
18. Viner R, Gregorowski A, Wine C, Bladen M, Fisher D, Miller M, El Neil S. Outpatient rehabilitative treatment of chronic fatigue syndrome (CFS/ME). *Arch Dis Child* 2004: 89(7): 615-619.
19. Crawley SA, Caporino NE, Birmaher B, Ginsburg G, Piacentini J, Albano AM, Sherrill J, Sakolsky D, Compton SN, Rynn M, McCracken J, Gosch E, Keeton C, March J, Walkup JT, Kendall PC. Somatic complaints in anxious youth. *Child Psychiatry Hum Dev* 2014: 45(4): 398-407.
20. Buonsenso D, Munblit D, De Rose C, Sinatti D, Ricchiuto A, Carfi A, Valentini P. Preliminary Evidence on Long Covid in children. *Acta Paediatr* 2021.
21. Sigfrid L, Drake TM, Pauley E, Jesudason EC, Olliaro P, Lim WS, Gillesen A, Berry C, Lowe DJ, McPeake J, Lone N, Cevik M, Munblit DJ, Casey A, Bannister P, Russell CD, Goodwin L, Ho A, Turtle L, O'Hara ME, Hastie C, Donohue C, Spencer R, Harrison J, Donegan C, Gummery A, Hardwick H, Hastie CE, Merson L, Carson G, Kenneth Baillie J, Openshaw PJ, Harrison EM, Docherty AB, Semple MG, Scott JT. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. *medRxiv* 2021: 2021.2003.2018.21253888.
22. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry* 2021.
23. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, Pujol JC, Klaser K, Antonelli M, Canas LS, Molteni E, Modat M, Jorge Cardoso M, May A, Ganesh S, Davies R, Nguyen LH, Drew DA, Astley CM, Joshi AD, Merino J, Tsereteli N, Fall T, Gomez MF, Duncan EL, Menni C, Williams FMK, Franks PW, Chan AT, Wolf J, Ourselin S, Spector T, Steves CJ. Attributes and predictors of long COVID. *Nat Med* 2021.
24. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, Banerjee A. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ* 2021: 372: n693.
25. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. *Int J Infect Dis* 2020: 100: 327-332.
26. Khamsi R. Rogue antibodies could be driving severe COVID-19. *Nature* 2021: 590(7844): 29-31.
27. Nekliudov NA, Blyuss O, Cheung KY, Petrou L, Genuneit J, Sushentsev N, Levadnaya A, Comberiati P, Warner JO, Tudor-Williams G, Teufel M, Greenhawt M, DunnGalvin A, Munblit D. Excessive Media Consumption About COVID-19 is Associated With Increased State Anxiety: Outcomes of a Large Online Survey in Russia. *J Med Internet Res* 2020: 22(9): e20955.

Figures



Figure 1. Flow diagram of patients with COVID-19 admitted to Z.A. Bashlyaeva Children's Municipal Clinical Hospital between April 2, 2020 and August 26, 2020. "Other" includes relatives unable to describe child health; relatives not willing to refer interviewers to the child parents/carers; inability to speak Russian.



Figure 2. Duration of the most common symptoms (post-discharge) in children who experienced symptoms at the time of discharge. The calculations are based on responses to the following questions: "Within the last seven days, has your child had any of these symptoms, which were NOT present prior to their Covid-19 illness? (If yes, please indicate below and the duration of the symptom/s) and "Please report any symptoms that have been bothering your child since discharge that are not present today. Please specify the time of onset and duration of these symptoms."



Figure 3. Upset plot representing coexistence of the persistent symptom (present at the time of the follow-up interview and lasting for over 5 months) categories at the follow-up assessment. The values represent the number of individuals experiencing a persistent symptom category or combination of categories. Black lines link multiple symptoms indicated by black dots.



Figure 4. Multivariable logistic regression model to identify pre-existing risk factors for post-COVID condition. Odds ratios and 95% CIs for presence of (A) any category of persistent symptoms (n=127) at the time of follow-up and (B) two or more co-existing categories of persistent symptoms (n=73) at the time of the follow-up. Neurological conditions include “neurological disorders” and/or “neurodisability”. Abbreviation: CI, confidence interval.

Characteristics	**Total**
Sex, female	270/518 (52.1%)
Age at the time of hospital admission, years (median, IQR)	10.4 (3-15.2)
Age (categorical), years	
<2	105 (20.3%)
2 – 5	80 (15.4%)
6 – 11	113 (21.8%)
12 – 18	220 (42.5%)
Days from discharge to follow-up (median, IQR)	256 (223-271)
Length of hospital admission (days, median, IQR)	10 (7-14)
Number of years of formal school education (median, IQR)	8 (4-9)
Number of members in household (median, IQR)	4 (3-5)
Pneumonia during hospitalisation	192/515 (37.3%)
Severe disease (non-invasive ventilation or invasive ventilation or PICU)	14/515 (2.7%)
Comorbidities	
Neurological conditions *Neurological disorders* *Neurodisability*	45/514 (8.8%) 43/514 (8.4%) 11/514 (2.1%)
Heart diseases	21/514 (4.1%)
Haematological conditions	10/514 (1.9%)
Tuberculosis	9/514 (1.8%)
Respiratory diseases (not including asthma)	16/514 (3.1%)
Allergic diseases† *Food Allergy* *Allergic Rhinitis* *Eczema* *Asthma (doctor diagnosed)*	121/514 (23.5%) 67/514 (13%) 46/514 (8.9%) 45/514 (8.8%) 12/514 (2.3%)
Other skin problems (not including eczema)	8/514 (1.6%)
Gastrointestinal problems	48/514 (9.3%)
Oncological conditions	3/514 (0.6%)
Immune system diseases	6/514 (1.2%)
Genetic conditions	6/514 (1.2%)
Diabetes*	3/514 (0.6%)
Other endocrine illness (not diabetes)	12/514 (2.3%)
Renal/Kidney problems	18/514 (3.5%)
Excessive weight and obesity	25/514 (4.9%)
Malnutrition	10/514 (1.9%)
Rheumatological conditions	4/514 (0.8%)
Depression	4/514 (0.8%)
Anxiety	5/514 (1%)
HIV	0 (0%)
No comorbidities	284/514 (55.3%)
One comorbidity	141/514 (27.4%)
Two comorbidities or more	89/514 (17.3%)

Table 1. Demographic characteristics of patients admitted to the Z.A. Bashlyaeva Children's Municipal Clinical Hospital. Data are n (%) or median (IQR) excluding missing values. *All cases of diabetes were type 1. †Allergic diseases include asthma, allergic rhinitis, food allergy and eczema.

Table of contents

Case Report Form (CRF) of Initial Survey: First Follow-Up Time Point version 1.0

The questions were answered by the:

□ Mother/female caregiver □ Father/male caregiver

Date you completed the survey (DD/MM/YYYY): [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]
What is your child's date of birth (DD/MM/YYYY): [_D_][_D_]/[_M_][_M_]/[_Y_][_Y_][_Y_][_Y_]

1. About your child

Sex/Gender: □ Male □ Female □ Prefer not to say

What is your child's estimated height (cm): _____ □ Not sure

What is your child's current estimated weight (kg): _____ □ Not sure

What was your child's estimated weight before Covid19 illness (kg): _____ □ Not sure

How many other members regularly live in your household, including yourself: [_Number_]

Does your child study in school/college/university? □ Yes □ No

How many years formal school education has your child had?* [_Number_]

including primary school (e.g. from around 6 years depending on country)

Does your child study in kindergarten? □ Yes □ No

2. About <u>your child's</u> Covid-19 illness - all the questions relate to his/her health and wellbeing)

Approximately, what day did you first notice your child was experiencing symptoms of Covid-19? [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]

How was your child diagnosed with Covid-19?

□ Laboratory confirmed (positive PCR, antigen or Antibody test) □ Physician confirmed □ Test result is uncertain

□ Not sure

Estimated date of your child's most recent positive SARS-CoV-2 /Covid-19 test:
[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_2_][_Y_]
Indicate if □PCR test □ Antibody test □ Unknown

Has your child been admitted to hospital due to Covid-19? □ Yes □ No

(If the answer is "no", please, move on to the section "3"; if the answer is "yes", please, proceed with the following questions)

- **Roughly at what date was your child first admitted to hospital?**
[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]
- **Roughly at what date was your child first discharged from hospital?**
[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]
- **If yes did they spent any time in the Paediatric Intensive Care Unit (PICU)?** □ Yes □ No □ Not sure
- **Has your child been admitted to hospital after the first acute Covid-19 illness?** □ Yes □ No

If yes, how many times: [_Number_]

Name of hospital/hospitals: _____

If yes, specify reason/reasons: _____

3. About your child's emotional wellbeing, social relationships and activities'

To answer the following questions, please **mark an X** on the lines below that shows your opinion on the question.

A. Compared to before your child's Covid-19 infection, how much is he/she now doing/experiencing the following

If there are changes, please indicate whether you think these are due to the illness itself or to the Covid-19 pandemic

Eating



□ Not known

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □ *Unsure*

Sleeping



□ Not known

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □ *Unsure*

Physical Activity



□ Not known

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □ *Unsure*

Fatigue



□ Not known

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □ *Unsure*

Spending time with friends in-person



□ Not known

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □ *Unsure*

Spending time with friends remotely (e.g., online, social media, texting)



□ Not known

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □ *Unsure*

Spending time watching TV, playing video/computer games, or using social media <u>for educational purposes</u>, including school/nursery work



□ Not known

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □ *Unsure*

Spending time watching TV, playing video/computer games, or using social media <u>for non-educational purposes</u>,



□ Not known

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □ *Unsure*

Spending time outside

Attending school/nursery



□ Not known

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □ *Unsure*



□ My child has not been attending school/nursery before Covid-19 infection

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □ *Unsure*

B. Compared to before your child's Covid-19 illness: Have there been changes in your child's…

… CONNECTEDNESS with others…



□ Unsure

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □*Unsure*

…EMOTIONS?



□ Unsure

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □*Unsure*

…BEHAVIOUR?



□ Unsure

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □*Unsure*

…RELATIONSHIPS, in how they get on with others?



□ Unsure

If there are changes, *please indicate whether you think these are due to*

□ *Illness itself* □ *Covid-19 pandemic* □ *Both* □*Unsure*

C. Have you asked for help from a health professional because of Covid-19 illness consequences to your child's EMOTIONS, BEHAVIOUR OR RELATIONSHIPS?

□ Yes □ No If yes who did you ask for help from_____

D. If you have replied MUCH WORSE to any of the options in question "B" OR YOU HAVE ASKED FOR HELP for these problems (question "C"), please, answer 3 of the following questions:

1. **Do the difficulties upset or distress your child?**

□ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal

2. **Do the difficulties interfere with your child's everyday life in the following areas?**

Home Life	□ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal
Friendships	□ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal
Classroom Learning	□ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal
Leisure Activities	□ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal

3. **Do these difficulties put a burden on you or the family as a whole?**

□ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal □ Unsure

E. Do you live in Moscow or Moscow Oblast? □ Yes □ No

If No,what is the current situation in your town/city/region on lockdown measures?

(you may select more than one answer)

□ Closing of child's school
□ Closing of nurseries/kindergartens
□ Closing of non-essential shops (shops and stores apart from food, doctors and drug stores)
□ Cancellation/closing of recreational venues and activities
□ Closing of indoor places/venues
□ Closing of outdoor recreational places
□ Constraining meeting friends
□ Stay-at-home orders (not allowed to leave the house except for essential errands)

4a. About your child's state of health prior to his/her Covid-19 illness

Has your child been physician's diagnosed or received treatment/support for any of the following chronic medical conditions prior to the Covid-19 infection? (answer with a tick in the box)

	Yes	No	Unknown
Prematurity *(baby born <37 weeks)*			
Neurological			
Neurodisability			
Heart diseases			
Respiratory diseases (not including asthma)			
Tuberculosis			
Asthma (doctor's diagnosed)			
Allergic rhinitis/hay fever			
Food allergy			
Atopic dermatitis/Eczema			
Other skin problems (not including eczema)			
Gut problems			
Haematology *(blood diseases)*			
Oncology *(cancer or other progressively enlarging or spreading tumor)*			
Immune system diseases (*e.g. primary immune deficiencies*)			
Genetic conditions			
Diabetes (if yes indicate type: □ Type 1 □ Type 2)			
Other endocrine illness (not diabetes)			
Renal/Kidney problems			
Excessive weight and obesity			
Malnutrition *(deficiencies, excesses, or imbalances in a person's intake of energy and/or nutrients)*			
Rheumatology *(e.g. arthritis, or inflammation of the joints)*			
Depression			
Anxiety			
HIV			
Other (please indicate)			

Has your child ever been under Child and Adolescent Mental Health services before the Covid-19 pandemic? □ Yes □ No □ Not sure

Prior to Covid-19 infection, how was your child's physical health in general?

□ Very poor □ Poor □ Ok □ Good □ Very good

If you ticked poor or very poor, please explain:

Prior to Covid-19 infection, how would you describe your child's mental health in general

□ Very poor □ Poor □ Ok □ Good □ Very good

If you ticked poor or very poor, please explain:_____

Have you requested help because of Covid-19 consequences to your child's physical health?

□ Yes □ No □ Not sure

4b. About your child's current health

Has your child felt feverish recently? □ Yes □ No □ Not sure

If yes indicate when they felt feverish (tick all that apply)

□ Within the last 7 days □ >1-2 weeks □ >2-4 weeks □ >1-2 months □ >2-3 months □ >3-6 months

□ >6 months ago

If yes, what was the most likely cause of your child's most recent feverish illness?

□ Covid-19 □ Other respiratory infection (cough/cold/sore throat) □ TB □ Stomach infection (diarrhea/vomiting) □ Urinary infection □ Other (specify): _____

□ Unknown □ Prefer not to say

If Covid-19, what was the estimated date of the most recent positive SARS-CoV-2 /Covid-19 test?

[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_2_][_Y_]
Indicate if □PCR test □ Antibody test □ Unknown

How much do you agree with the following statement?
"My child has fully recovered from Covid-19"

Please **mark an X** on the line below that shows your opinion on the question as of **TODAY**



5. Since having Covid-19, has your child been diagnosed with any of the following? (indicate the correct answer in the box provided)

	YES	NO		YES	NO
Multisystem inflammatory syndrome			Shock / Toxic shock syndrome		
Pulmonary embolism *(PE, "Clot in lung")*			Coagulopathy *(excessive bleeding or clotting)*		
Kawasaki disease			Kidney problems		
Multisystem inflammatory syndrome (MIS-C/PIMS-TS)			Type 1 Diabetes		
Respiratory failure			Type 2 Diabetes		
Asthma			Intussusception		
Myocarditis *(inflammation of the heart muscle)*			Other condition (if yes specify):		

6a. Within the last seven days, has your child had any of these symptoms, which were NOT present prior to their Covid-19 illness? If yes, please indicate below and the duration of the symptom/s:

Respiratory problems	**Tick Yes or No**	**If yes**, what is the duration of symptoms
Nasal congestion / rhinorrhea	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Difficulty breathing /chest tightness	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Pain on breathing	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Chest pain	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Persistent cough	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
If yes, □ dry cough □ with phlegm		
Musculoskeletal problems	**Tick Yes or No**	**If yes**, what is the duration of symptoms
Cannot fully move or control movement	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Problems with balance	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Persistent muscle pain	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure

Joint pain or swelling	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Neurological problems	**Tick Yes or No**	**If yes**, what is the duration of symptoms
Headache	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Dizziness/ light headedness	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Fainting/ blackouts	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Problems seeing/blurred vision	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Disturbed smell	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Loss of smell	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Disturbed taste	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Loss of taste	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Tremor/shakiness	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Tingling feeling/ “pins and needles“	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months

		□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Seizures/fits	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Confusion/lack of concentration	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Problems speaking or communicating	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Insomnia *(hard to fall asleep, hard to stay asleep)*	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Hypersomnia *(excessive daytime sleepiness or prolonged nighttime sleep)*	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Fatigue	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Gastrointestinal problems	**Tick Yes or No**	**If yes**, what is the duration of symptoms
Weight loss	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Problems swallowing or chewing	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Poor appetite	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Diarrhea	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure

Stomach/ abdominal pain	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Feeling nauseous	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Vomiting	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Constipation	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Cardiovascular problems	**Tick Yes or No**	**If yes**, what is the duration of symptoms
Palpitations (heart racing)	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Variations in heart rate (tachycardia or bradycardia)	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Bleeding	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
If yes, specify bleeding site:		
Genitourinary problems	**Tick Yes or No**	**If yes**, what is the duration of symptoms
Urination problems	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Changes in menstruation, (if regular before Covid-19 illness)	□ Yes □ No □ Not applicable	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Other problems	**Tick Yes or No**	**If yes**, what is the duration of symptoms
Bilateral conjunctivitis *If yes, □ purulent □ non-purulent*	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months

		□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Lumps or rashes (purple/pink) on toes	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Skin rash	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Skin rash *If yes, tick all body areas that apply:*	□ Yes □ No	□ Face □ Trunk (stomach or back) □ Arms □ Legs □ Buttocks □ Toes □ Fingers □ Accompanied by itch
Hair loss	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Hyperhidrosis	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
Other New Symptoms, if yes, specify all with their duration:		**If yes**, what is the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure

6b. Please report any symptoms that have been bothering your child since discharge that are not present today. Please specify the time of onset and duration of these symptoms

Respiratory problems	**Tick Yes or No**	**If yes**, what was the time of onset
Nasal congestion / rhinorrhea	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Difficulty breathing /chest tightness	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Pain on breathing	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Chest pain	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Persistent cough	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months

		□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
If yes, □ dry cough □ with phlegm		
Musculoskeletal problems	**Tick Yes or No**	**If yes**, what was the time of onset
Cannot fully move or control movement	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Problems with balance	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Persistent muscle pain	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Joint pain or swelling	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure

Neurological problems	Tick Yes or No	If yes, what was the time of onset
Headache	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Dizziness/ light headedness	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Fainting/ blackouts	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Problems seeing/blurred vision	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Disturbed smell	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months

		□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Loss of smell	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Disturbed taste	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Loss of taste	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Tremor/shakiness	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Tingling feeling/ “pins and needles“	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure

		If yes, what was the duration of symptoms □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Seizures/fits	□ Yes □ No	**If yes**, what was the time of onset □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure **If yes**, what was the duration of symptoms □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Confusion/lack of concentration	□ Yes □ No	**If yes**, what was the time of onset □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure **If yes**, what was the duration of symptoms □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Problems speaking or communicating	□ Yes □ No	**If yes**, what was the time of onset □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure **If yes**, what was the duration of symptoms □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Insomnia *(hard to fall asleep, hard to stay asleep)*	□ Yes □ No	**If yes**, what was the time of onset □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure **If yes**, what was the duration of symptoms □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Hypersomnia *(excessive daytime sleepiness or prolonged nighttime sleep)*	□ Yes □ No	**If yes**, what was the time of onset □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months

		□ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Fatigue	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Gastrointestinal problems	**Tick Yes or No**	**If yes**, what was the time of onset
Weight loss	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Problems swallowing or chewing	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Poor appetite	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure

Diarrhea	□ Yes □ No	**If yes**, what was the time of onset □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure **If yes**, what was the duration of symptoms □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Stomach/ abdominal pain	□ Yes □ No	**If yes**, what was the time of onset □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure **If yes**, what was the duration of symptoms □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Feeling nauseous	□ Yes □ No	**If yes**, what was the time of onset □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure **If yes**, what was the duration of symptoms □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Vomiting	□ Yes □ No	**If yes**, what was the time of onset □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure **If yes**, what was the duration of symptoms □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Constipation	□ Yes □ No	**If yes**, what was the time of onset □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure **If yes**, what was the duration of symptoms □ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months

		□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Cardiovascular problems	**Tick Yes or No**	**If yes**, what was the time of onset
Palpitations (heart racing)	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Variations in heart rate (tachycardia or bradycardia)	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Bleeding	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
If yes, specify bleeding site:		
Genitourinary problems	**Tick Yes or No**	**If yes**, what was the time of onset
Urination problems	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Changes in menstruation, (if regular before Covid-19 illness)	□ Yes □ No □ Not applicable	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months

		□ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Other problems	**Tick Yes or No**	**If yes**, what was the time of onset
Bilateral conjunctivitis *If yes, □ purulent □ non-purulent*	□ Yes □ No	□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Lumps or rashes (purple/pink) on toes	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Skin rash	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Skin rash *If yes, tick all body areas that apply:*	□ Yes □ No	□ *Face*
		□ *Trunk (stomach or back)*
		□ *Arms*
		□ *Legs*
		□ *Buttocks*
		□ *Toes*
		□ *Fingers*
		□ *Accompanied by itch*
Hair loss	□ Yes □ No	**If yes**, what was the time of onset

		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Hyperhidrosis	□ Yes □ No	**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure
Other New Symptoms, if yes, specify all with their onset and duration:		**If yes**, what was the time of onset
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ From the time of discharge □ Not sure
		If yes, what was the duration of symptoms
		□ < 1 month □ 1-2 months □ >2 -3 months □ >3-4 months □ >4-5 months □ >5-6 months □ >6-7 months □ >7 -8 months □ >8-9 months □ >9 -10 months □ >10-11 months □ >11 -12 months □ >12 months □ Not sure

7. Your child's overall health status

We would like to know how good or bad your child's health was **BEFORE Covid-19** and how it is **TODAY**

This scale is numbered from 0 to 100%
with **100% meaning the best health** you can imagine
0% means the worst health you can imagine.

Please indicate on the scale and **write the number in the box below each scale** to indicate how good or bad your child's health was **BEFORE Covid-19** and how it is **TODAY**.



8. Vaccinations

Has your child been vaccinated in accordance with the national vaccination schedule?

□ Yes, vaccinated up to date □ Yes, but some vaccines were missed □ No, I avoid vaccination for my child

Please provide an approximate date of your child's latest vaccination?
[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]

Please, specify what was the vaccine: _____ □ I do not remember

I trust information I receive about vaccines?
□ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal

How confident are you in any of the childhood vaccines safety?

□ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal

Has your child been vaccinated against Covid-19? □ Yes □ No □ Not sure

If yes, how many times have they had the Covid-19 vaccine? [_Number_]

Estimated date of the last vaccine dose received: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_2_][_Y_]

Which type of Covid-19 vaccine did they receive: □AstraZeneca □Pfizer-BioNTech
□Imperial □Janssens □Moderna's □Sinopharm □Sputnik V □Other (name): _____ □Not sure

<u>If no</u>, would you like to vaccinate your child against Covid-19 in the future? □ Yes □ No □ Not sure

I trust information I receive about Covid-19 vaccination?
□ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal

How confident are you in the safety of Covid-19 vaccinations?
□ Not at all □ Only a little □ Undecided □ Quite a lot □ A great deal

What is your opinion of Russian-made vaccines against Covid-19?
□ Negative □ Neutral □ Positive □ Not sure

What is your opinion of vaccines against Covid-19 produced abroad?
□ Negative □ Neutral □ Positive □ Not sure

9. Some questions about you

During your child's illness, have you often been in a bad mood, depressed or feeling hopeless?	□ Yes □ No
During your child's illness, did you often feel that everything was difficult, and you did not want to do anything?	□ Yes □ No
During your child's illness, did you often feel persistent fatigue for no reason?	□ Yes □ No
Did your child's illness often make you feel nervous, anxious or extremely stressed?	□ Yes □ No
Did your child's illness often leave you unable to calm down or have you often been unable to calm or control your worries?	□ Yes □ No
Due to your child's illness, have you often experienced fear, as if something terrible were about to happen?	□ Yes □ No
Due to your child's illness, have you had to face aggressive or prejudiced attitudes from others?	□ Yes □ No
Did you receive enough help and support during your child's illness?	□ Yes □ No

10. Please let us know of any further comments about the child's illness, the pandemic, lockdown and/or any sequelae.

11. End of survey

Thank you for your time!

Table S1. Categorisation of persistent symptoms at follow-up.

Symptom category	Persistent symptoms included
Musculoskeletal	joint pain or swelling OR persistent muscle pain
Cardiovascular	variations in heart rate OR palpitations
Respiratory	difficulty breathing/chest tightness OR pain on breathing OR persistent cough
Neurological	cannot fully move or control movement OR problems with balance OR confusion/lack of concentration OR problems speaking or communicating OR seizures/fits OR tingling feeling/ 'pins and needles' OR tremor/shakiness OR dizziness/light headedness OR fainting/ blackouts
Dermatological	skin rash OR lumps or rashes (purple/pink) on toes OR hair loss
Gastrointestinal	constipation OR diarrhea OR feeling nauseous OR stomach/ abdominal pain OR vomiting
Sensory	disturbed smell OR disturbed taste OR loss of smell OR loss of taste
Sleep	hypersomnia OR insomnia
Fatigue	fatigue

Table S2. Symptoms at the time of hospital admission.

Characteristics	Results
History of fever	427/511 (83.6%)
Cough	284/510 (55.7%)
Fatigue	197/506 (38.9%)
Rhinorrhoea	278/512 (54.3%)
Shortness of breath	77/513 (15%)
Disturbed smell or loss of smell	64/456 (14%)
Sore throat	67/487 (13.8%)
Lymphadenopathy	52/512 (10.2%)
Headache	40/465 (8.6%)
Diarrhoea	43/511 (8.4%)
Skin rash	41/512 (8%)
Wheezing	39/512 (7.6%)
Vomiting / Nausea	32/512 (6.2%)
Chest pain	28/464 (6%)
Abdominal pain	27/489 (5.5%)
Disturbed taste or Loss of taste	16/456 (3.5%)
Muscle aches	14/463 (3%)
Conjunctivitis	10/512 (2%)
Joint pain	5/461 (1.1%)
Ear pain	3/463 (0.6%)
Seizures	3/512 (0.6%)
Bleeding	3/512 (0.6%)
Lower chest wall indrawing	3/512 (0.6%)
Confusion	2/511 (0.4%)

The differing denominators used indicate missing data.

Table S3. Most commonly used treatments during the hospital stay.

Characteristics	Total
Antiviral or COVID-19 targeted agent	394/512 (77.0%)
Antibiotics	380/513 (74.1%)
Mucolytics	188/513 (36.7%)
Arbidol	133/512 (26%)
Antifungal agent	25/513 (4.9%)
Corticosteroid	20/513 (3.9%)
Heparin	17/513 (3.3%)

The differing denominators used indicate missing data.

Table S4. Symptoms reported at the time of the follow-up interview and symptom duration (in months).

Current symptom	Total number of patients with the symptom	Total number of patients with the persistent symptom	< 1	1-2	> 2-3	> 3-4	> 4-5	> 5-6	> 6-7	> 7-8	> 8-9	> 9-10	From the time of discharge
Fatigue	63/498 (12.65%)	53/496 (10.69%)	5/496 (1.01%)	1/496 (0.2%)	0/496 (0%)	1/496 (0.2%)	1/496 (0.2%)	4/496 (0.81%)	1/496 (0.2%)	2/496 (0.4%)	1/496 (0.2%)	0/496 (0%)	45/496 (9.07%)
Nasal congestion/ rhinorrhea	43/505(8.51%)	10/505 (1.98%)	29/505 (5.74 %)	2/505 (0.4%)	1/505 (0.2 %)	1/505 (0.2%)	0/505 (0%)	0/505 (0%)	0/505 (0%)	0/505 (0%)	0/505 (0%)	0/505 (0%)	10/505 (1.98 %)
Insomnia	32/501 (6.39%)	26/501 (5.19%)	2/501 (0.4%)	2/501 (0.4%)	1/501 (0.2%)	0/501 (0%)	1/501 (0.2%)	2/501 (0.4%)	1/501 (0.2%)	1/501 (0.2%)	0/501 (0%)	0/501 (0%)	22/501 (4.39%)
Disturbed smell	26/468 (5.56%)	22/467 (4.71%)	0/467 (0%)	2/467 (0.43%)	1/467 (0.21%)	0/467 (0%)	0/467 (0%)	3/467 (0.64%)	0/467 (0%)	2/467 (0.43%)	0/467 (0%)	0/467 (0%)	17/467 (3.64%)
Headache	24/488(4.92%)	17/486 (3.5%)	4/486 (0.82%)	0/486 (0%)	1/486 (0.21%)	0/486 (0%)	0/486 (0%)	1/486 (0.21%)	0/486 (0%)	0/486 (0%)	0/486 (0%)	0/486 (0%)	16/486 (3.29%)
Disturbed taste	18/468 (3.85%)	16/468 (3.42%)	0/468 (0%)	1/468 (0.21%)	1/468 (0.21%)	0/468 (0%)	0/468 (0%)	2/468 (0.43%)	0/468 (0%)	2/468 (0.43%)	0/468 (0%)	0/468 (0%)	12/468 (2.56%)
Hyperhidrosis	17/502(3.39%)	13/502 (2.59%)	1/502 (0.2%)	2/502 (0.4%)	0/502 (0%)	1/502 (0.2%)	0/502 (0%)	0/502 (0%)	0/502 (0%)	1/502 (0.2%)	0/502 (0%)	0/502 (0%)	12/502 (2.39%)
Persistent cough	17/503 (3.38%)	5/503 (0.99%)	9/503 (1.79%)	3/503 (0.6%)	0/503 (0%)	0/503 (0%)	0/503 (0%)	0/503 (0%)	0/503 (0%)	0/503 (0%)	0/503 (0%)	0/503 (0%)	5/503 (0.99%)
Hypersomnia	16/501 (3.19%)	15/501 (2.99%)	0/501 (0%)	0/501 (0%)	0/501 (0%)	1/501 (0.2%)	0/501 (0%)	1/501 (0.2%)	1/501 (0.2%)	1/501 (0.2%)	1/501 (0.2%)	0/501 (0%)	11/501 (2.2%)
Poor appetite	15/500 (3%)	12/500 (2.4%)	2/500 (0.4%)	0/500 (0%)	1/500 (0.2%)	0/500 (0%)	0/500 (0%)	1/500 (0.2%)	0/500 (0%)	1/500 (0.2%)	1/500 (0.2%)	0/500 (0%)	9/500 (1.8%)
Skin rash	13/497 (2.62%)	8/497 (1.61%)	3/497 (0.6%)	0/497 (0%)	1/497 (0.2%)	0/497 (0%)	1/497 (0.2%)	2/497 (0.4%)	0/497 (0%)	0/497 (0%)	0/497 (0%)	0/497 (0%)	6/497 (1.21%)
Diarrhea	13/499 (2.61%)	10/499 (2%)	1/499 (0.2%)	0/499 (0%)	1/499 (0.2%)	0/499 (0%)	1/499 (0.2%)	0/499 (0%)	0/499 (0%)	1/499 (0.2%)	0/499 (0%)	0/499 (0%)	9/499 (1.8%)
Stomach/ abdominal pain	13/499 (2.61%)	10/499 (2%)	1/499 (0.2%)	1/499 (0.2%)	1/499 (0.2%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	1/499 (0.2%)	0/499 (0%)	0/499 (0%)	9/499 (1.8%)
Problems seeing/ blurred vision	12/480 (2.5%)	10/479 (2.09%)	0/479 (0%)	0/479 (0%)	1/479 (0.21%)	0/479 (0%)	0/479 (0%)	1/479 (0.21%)	1/479 (0.21%)	0/479 (0%)	0/479 (0%)	0/479 (0%)	8/479 (1.67%)
Hair loss	12/501 (2.4%)	9/501 (1.8%)	0/501 (0%)	1/501 (0.2%)	2/501 (0.4%)	0/501 (0%)	0/501 (0%)	1/501 (0.2%)	1/501 (0.2%)	1/501 (0.2%)	0/501 (0%)	0/501 (0%)	6/501 (1.2%)
Dizziness/ light headedness	10/486 (2.06%)	5/484 (1.03%)	2/484 (0.41%)	1/484 (0.21%)	0/484 (0%)	0/484 (0%)	0/484 (0%)	0/484 (0%)	0/484 (0%)	0/484 (0%)	0/484 (0%)	0/484 (0%)	5/484 (1.03%)
Joint pain or swelling	10/493 (2.03%)	6/492 (1.22%)	1/492 (0.2%)	2/492 (0.41%)	0/492 (0%)	0/492 (0%)	0/492 (0%)	0/492 (0%)	0/492 (0%)	1/492 (0.2%)	0/492 (0%)	0/492 (0%)	5/492 (1.02%)
Variations in heart rate	10/494 (2.02%)	6/493 (1.22%)	0/493 (0%)	0/493 (0%)	1/493 (0.2%)	0/493 (0%)	0/493 (0%)	0/493 (0%)	0/493 (0%)	1/493 (0.2%)	0/493 (0%)	0/493 (0%)	5/493 (1.01%)
Constipation	9/500 (1.8%)	8/500 (1.6%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	1/500 (0.2%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	8/500 (1.6%)
Loss of smell	8/468 (1.71%)	7/468 (1.5%)	0/468 (0%)	1/468 (0.21%)	0/468 (0%)	0/468 (0%)	0/468 (0%)	0/468 (0%)	0/468 (0%)	0/468 (0%)	0/468 (0%)	0/468 (0%)	7/468 (1.5%)
Difficulty breathing /chest	8/503 (1.59%)	7/503 (1.39%)	1/503 (0.2 %)	0/503 (0%)	0/503 (0%)	0/503 (0%)	0/503 (0%)	1/503 (0.2 %)	0/503 (0%)	0/503 (0%)	0/503 (0%)	0/503 (0%)	6/503 (1.19 %)

tightness													
Palpitations	7/472(1.48%)	5/471 (1.06%)	0/471 (0%)	0/471 (0%)	1/471 (0.21%)	0/471 (0%)	0/471 (0%)	0/471 (0%)	0/471 (0%)	1/471 (0.21%)	0/471 (0%)	0/471 (0%)	4/471 (0.85%)
Feeling nauseous	7/500 (1.4%)	6/500 (1.2%)	1/500 (0.2%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	1/500 (0.2%)	1/500 (0.2%)	0/500 (0%)	0/500 (0%)	4/500 (0.8%)
Chest pain	6/487(1.23%)	3/487 (0.62%)	2/487 (0.41 %)	0/487 (0%)	1/487 (0.21 %)	0/487 (0%)	0/487 (0%)	0/487 (0%)	0/487 (0%)	0/487 (0%)	0/487 (0%)	0/487 (0%)	3/487 (0.62 %)
Persistent muscle pain	6/491(1.22%)	4/490 (0.82%)	1/490 (0.2%)	0/490 (0%)	0/490 (0%)	0/490 (0%)	0/490 (0%)	0/490 (0%)	0/490 (0%)	1/490 (0.2%)	0/490 (0%)	0/490 (0%)	3/490 (0.61%)
Problems with balance	6/496(1.21%)	2/494 (0.4%)	1/494 (0.2%)	1/494 (0.2%)	0/494 (0%)	0/494 (0%)	0/494 (0%)	0/494 (0%)	0/494 (0%)	0/494 (0%)	0/494 (0%)	0/494 (0%)	2/494 (0.4%)
Urination problems	4/496 (0.81%)	3/496 (0.6%)	1/496 (0.2%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	1/496 (0.2%)	2/496 (0.4%)
Vomiting	4/500 (0.8%)	4/500 (0.8%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	1/500 (0.2%)	0/500 (0%)	3/500 (0.6%)
Confusion/ lack of concentration	3/486 (0.62%)	2/486 (0.41%)	0/486 (0%)	0/486 (0%)	0/486 (0%)	0/486 (0%)	1/486 (0.21%)	1/486 (0.21%)	0/486 (0%)	0/486 (0%)	0/486 (0%)	0/486 (0%)	1/486 (0.21%)
Pain on breathing	3/488(0.61%)	2/488 (0.41%)	0/488 (0%)	0/488 (0%)	1/488 (0.2 %)	0/488 (0%)	0/488 (0%)	0/488 (0%)	0/488 (0%)	0/488 (0%)	0/488 (0%)	0/488 (0%)	2/488 (0.41%)
Cannot fully move or control movement	3/499(0.6%)	2/499 (0.4%)	0/499 (0%)	1/499 (0.2%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	2/499 (0.4%)
Tremor/ shakiness	3/500 (0.6%)	3/500 (0.6%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	3/500 (0.6%)
Bleeding	3/497 (0.6%)	1/497 (0.2%)	0/497 (0%)	1/497 (0.2%)	1/497 (0.2%)	0/497 (0%)	0/497 (0%)	0/497 (0%)	0/497 (0%)	0/497 (0%)	0/497 (0%)	0/497 (0%)	1/497 (0.2%)
Changes in menstruation	3/501 (0.6%)	3/501 (0.6%)	0/501 (0%)	0/501 (0%)	0/501 (0%)	0/501 (0%)	0/501 (0%)	0/501 (0%)	1/501 (0.2%)	0/501 (0%)	0/501 (0%)	0/501 (0%)	2/501 (0.4%)
Loss of taste	2/469(0.43%)	2/469 (0.43%)	0/469 (0%)	0/469 (0%)	0/469 (0%)	0/469 (0%)	0/469 (0%)	0/469 (0%)	0/469 (0%)	0/469 (0%)	0/469 (0%)	0/469 (0%)	2/469 (0.43%)
Tingling feeling/ “pins and needles“	2/472 (0.42%)	2/472 (0.42%)	0/472 (0%)	1/472 (0.21%)	0/472 (0%)	0/472 (0%)	0/472 (0%)	0/472 (0%)	1/472 (0.21%)	0/472 (0%)	0/472 (0%)	0/472 (0%)	0/472 (0%)
Weight loss	2/500 (0.4%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	1/500 (0.2%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)	0/500 (0%)
Problems swallowing or chewing	2/499 (0.4%)	1/499 (0.2%)	1/499 (0.2%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	0/499 (0%)	1/499 (0.2%)
Bilateral conjunctivitis	2/496 (0.4%)	2/496 (0.4%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	0/496 (0%)	2/496 (0.4%)
Seizures/fits	1/498 (0.2%)	0/498 (0%)	0/498 (NaN%)	0/498 (NaN%)	0/498 (NaN%)	0/498 (NaN%)	0/498 (NaN%)	0/498 (NaN%)	0/498 (NaN%)	0/498 (NaN%)	0/498 (NaN%)	0/498 (NaN%)	0/498 (NaN%)
Lumps or rashes (purple/pink) on toes	1/495 (0.2%)	1/495 (0.2%)	0/495 (0%)	0/495 (0%)	0/495 (0%)	0/495 (0%)	0/495 (0%)	0/495 (0%)	0/495 (0%)	0/495 (0%)	0/495 (0%)	0/495 (0%)	1/495 (0.2%)

Problems speaking or communicating	1/489 (0.2%)	1/489 (0.2%)	0/489 (0%)	0/489 (0%)	0/489 (0%)	0/489 (0%)	0/489 (0%)	0/489 (0%)	0/489 (0%)	0/489 (0%)	0/489 (0%)	0/489 (0%)	1/489 (0.2%)
Fainting/ blackouts	0/497 (0%)	0/497 (0%)	0/497 (NaN%)	0/497 (NaN%)	0/497 (NaN%)	0/497 (NaN%)	0/497 (NaN%)	0/497 (NaN%)	0/497 (NaN%)	0/497 (NaN%)	0/497 (NaN%)	0/497 (NaN%)	0/497 (NaN%)

The differing denominators used indicate missing data.

Table S4. Parental perception of mood and behaviour changes in their children.

Characteristic	**Likert scale response**							**Reasons of changes**			
	1 (less)	**2**	**3 (the same)**	**4**	**5 (more)**	**Not known**	**Other**	**Illness itself**	**Covid-19 pandemic**	**Both**	**Unsure**
Eating	14 (2.7%)	23 (4.5%)	445 (86.4%)	9 (1.7%)	10 (1.9%)	3 (0.6%)	11 (2.1%)	28 (49.1%)	4 (7%)	2 (3.5%)	23 (40.4%)
Sleeping	15 (2.9%)	23 (4.5%)	447 (86.8%)	5 (1%)	11 (2.1%)	4 (0.8%)	10 (1.9%)	28 (52.8%)	7 (13.2%)	4 (7.5%)	14 (26.4%)
Physical activity	27 (5.2%)	33 (6.4%)	429 (83.3%)	9 (1.7%)	4 (0.8%)	3 (0.6%)	10 (1.9%)	26 (37.7%)	22 (31.9%)	5 (7.2%)	16 (23.2%)
Fatigue	3 (0.6%)	11 (2.1%)	400 (77.8%)	39 (7.6%)	48 (9.3%)	4 (0.8%)	9 (1.8%)	53 (53%)	11 (11%)	16 (16%)	20 (20%)
Spending time with friends in-person	31 (6.2%)	27 (5.4%)	392 (78.1%)	19 (3.8%)	6 (1.2%)	17 (3.4%)	10 (2%)	4 (4.8%)	66 (78.6%)	7 (8.3%)	7 (8.3%)
Spending time with friends remotely	1 (0.2%)	5 (1%)	397 (80.4%)	27 (5.5%)	37 (7.5%)	24 (4.9%)	3 (0.6%)	2 (2.8%)	58 (81.7%)	7 (9.9%)	4 (5.6%)
Spending time watching TV, playing video/computer games, or using social media for educational purposes, including school/nursery work	2 (0.4%)	2 (0.4%)	360 (71.9%)	42 (8.4%)	68 (13.6%)	23 (4.6%)	4 (0.8%)	2 (1.8%)	105 (92.9%)	2 (1.8%)	4 (3.5%)
Spending time watching TV, playing video/computer games, or using social media for non-educational purposes	4 (0.8%)	9 (1.8%)	408 (81.8%)	20 (4%)	28 (5.6%)	24 (4.8%)	6 (1.2%)	2 (3.4%)	44 (75.9%)	2 (3.4%)	10 (17.2%)
Spending time outside	36 (7.1%)	39 (7.7%)	364 (71.5%)	35 (6.9%)	18 (3.5%)	6 (1.2%)	11 (2.2%)	5 (4.1%)	89 (73%)	11 (9%)	17 (13.9%)
Attending school/nursery	29 (5.7%)	7 (1.4%)	313 (61.9%)	4 (0.8%)	36 (7.1%)	102 (20.2%)	15 (3%)	3 (3.7%)	65 (79.3%)	2 (2.4%)	12 (14.6%)
Connectedness	4 (0.8%)	20 (4%)	456 (91%)	4 (0.8%)	1 (0.2%)	13 (2.6%)	3 (0.6%)	3 (10.7%)	14 (50%)	5 (17.9%)	6 (21.4%)
Emotions	11 (2.2%)	57 (11.2%)	411 (80.4%)	11 (2.2%)	3 (0.6%)	5 (1%)	13 (2.5%)	24 (29.6%)	16 (19.8%)	10 (12.3%)	31 (38.3%)
Behaviour	5 (1%)	37 (7.2%)	438 (85.5%)	8 (1.6%)	3 (0.6%)	5 (1%)	16 (3.1%)	16 (28.1%)	7 (12.3%)	6 (10.5%)	28 (49.1%)
Relationships	1 (0.2%)	14 (2.8%)	481 (95.2%)	1 (0.2%)	0 (0%)	5 (1%)	3 (0.6%)	7 (46.7%)	2 (13.3%)	3 (20%)	3 (20%)

The differing denominators used indicate missing data.

Table S5. Parental-reported mood and behaviour changes due to Covid-19 and pandemic in their children, stratified by the the effect.

Characteristic	Caused by illness itself		Caused by Covid-19 pandemic	
	Less	***More***	***Less***	***More***
Eating	23/512 (4.5%)	4/512 (0.8%)	0 (0%)	4/512 (0.8%)
Sleeping	18/511 (3.5%)	10/511 (2%)	6/511 (1.2%)	1/511 (0.2%)
Physical activity	24/512 (4.7%)	2/512 (0.4%)	19/512 (3.7%)	3/512 (0.6%)
Fatigue	7/510 (1.4%)	46/510 (9%)	1/510 (0.2%)	10/510 (2%)
Spending time with friends in-person	2/485 (0.4%)	2/485 (0.4%)	47/485 (9.7%)	19/485 (3.9%)
Spending time with friends remotely	2/470 (0.4%)	0 (0%)	2/470 (0.4%)	55/470 (11.7%)
Spending time watching TV, playing video/computer games, or using social media for educational purposes, including school/nursery work	1/478 (0.2%)	1/478 (0.2%)	0 (0%)	105/478 (22%)
Spending time watching TV, playing video/computer games, or using social media for non-educational purposes	1/475 (0.2%)	1/475 (0.2%)	3/475 (0.6%)	41/475 (8.6%)
Spending time outside	5/503 (1%)	0 (0%)	49/503 (9.7%)	39/503 (7.8%)
Attending school/nursery	2/404 (0.5%)	1/404 (0.3%)	29/404 (7.2%)	36/404 (8.9%)
Connectedness	2/488 (0.4%)	1/488 (0.2%)	13/488 (2.7%)	1/488 (0.2%)
Emotions	22/511 (4.3%)	2/511 (0.4%)	13/511 (2.5%)	2/511 (0.4%)
Behaviour	14/506 (2.8%)	1/506 (0.2%)	0 (0%)	7/506 (1.4%)
Relationships	7/500 (1.4%)	0 (0%)	2/500 (0.4%)	0 (0%)

The differing denominators used indicate missing data.

Figure S1. The proportion of COVID-19 infected children who at various time points after discharge from hospital had one or more of the commonest continuing symptoms. Some children had more than one symptom.



The prevalence was calculated based on responses to the following questions: “Within the last seven days, has your child had any of these symptoms, which were NOT present prior to their Covid-19 illness? (If yes, please indicate below and the duration of the symptom/s) and “Please report any symptoms that have been bothering your child since discharge that are not present today. Please specify the time of onset and duration of these symptoms.”

Figure S2. Multivariable logistic regression model to identify pre-existing risk factors for post-COVID condition (using age as a continuous variable). Odds ratios and 95% CIs for presence of (A) any category of persistent symptoms at the time of follow-up and (B) two or more co-existing categories of persistent symptoms at the time of the follow-up. Neurological conditions include "neurological disorders" and/or "neurodisability". Abbreviation: CI, confidence interval.





Figure S3. Multivariable logistic regression model to identify pre-existing risk factors for post-COVID condition (subgroup analyses in children ≥6 years of age). Odds ratios and 95% CIs for presence of (A) any category of persistent symptoms at the time of follow-up and (B) two or more co-existing categories of persistent symptoms at the time of the follow-up. Neurological conditions include "neurological disorders" and/or "neurodisability". Abbreviation: CI, confidence interval.